| Literature DB >> 28700032 |
Y Fan1,2, J-S Hu2, F Guo2, Z-B Lu1, H Xia1.
Abstract
As a mechanism compensating for obstructive coronary artery disease, coronary collateral circulation (CCC) has attracted cardiologists for a long time to explore its potential impact. In the present study, Chinese patients suffering from ≥95% coronary stenosis, as diagnosed by angiography, have been investigated for the correlation between CCC and lipoprotein(a) [Lp(a)] levels. A cohort of 654 patients was divided into four categories according to Rentrop grades 0, 1, 2, and 3. Lp(a) levels were divided into model 1, discretized with critical values of 33 and 66%, and model 2, discretized with a cutoff value of 30.0 mg/dL. Furthermore, we evaluated the correlation between CCC and serum Lp(a) levels. The four groups had significantly different Lp(a) levels (25.80±24.72, 18.99±17.83, 15.39±15.80, and 8.40±7.75 mg/dL; P<0.001). In model 1, concerning R0, the risk in the third Lp (a) tertile (OR=3.34, 95%CI=2.32-4.83) was greater than that in the first tertile. In model 2, concerning R0, the risk in Lp(a) >30.0 group (OR=6.77, 95%CI=4.44-10.4) was greater than that of Lp(a) <30.0 mg/dL. The worst condition of CCC can be predicted independently by Lp(a) levels. In addition to clinical usage, Lp(a) levels can also be utilized as biological markers.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28700032 PMCID: PMC5505520 DOI: 10.1590/1414-431X20175979
Source DB: PubMed Journal: Braz J Med Biol Res ISSN: 0100-879X Impact factor: 2.590
Figure 1.Flow diagram of patient recruitment. CAD: coronary artery disease; ACS: acute coronary syndrome; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; LVEF: left ventricular ejection fraction; COPD: chronic obstructive pulmonary disease.
Baseline characteristics of the patients.
| Variables | Rentrop collateral classification | P | |||
|---|---|---|---|---|---|
| 0 (n=44) | 1 (n=91) | 2 (n=232) | 3 (n=287) | ||
| Clinical characteristics | |||||
| Age (years) | 58.82±9.57 | 56.21±9.66 | 57.01±9.83 | 55.32±9.40 | 0.064 |
| Male (n, %) | 32 (72.73%) | 69 (75.82%) | 188 (81.03%) | 236 (82.23%) | 0.321 |
| BMI (kg/m2) | 26.54±2.96 | 26.05±3.12 | 25.78±3.32 | 26.13±3.03 | 0.393 |
| Current smokers (n, %) | 13 (29.55%) | 30 (32.97%) | 84 (36.21%) | 102 (35.54%) | 0.819 |
| Drinking (n, %) | 7 (15.91%) | 15 (16.48%) | 58 (25.00%) | 58 (20.21%) | 0.247 |
| Hypertension (n, %) | 32 (72.73%) | 59 (64.84%) | 152 (65.52%) | 182 (63.41%) | 0.682 |
| Diabetes mellitus (n, %) | 20 (45.45%) | 38 (41.76%) | 68 (29.31%) | 63 (21.95%) | 0.000 |
| Previous MI (n, %) | 13 (29.55%) | 21 (23.08%) | 67 (28.88%) | 77 (26.83%) | 0.740 |
| Previous PCI (n, %) | 13 (29.55%) | 26 (28.57%) | 47 (20.26%) | 59 (20.56%) | 0.215 |
| Laboratory findings | |||||
| LP(a) (mg/dL) | 25.80±24.72 | 18.99±17.83 | 15.39±15.80 | 8.40±7.75 | 0.000 |
| LP(a) (Lg) | 5.13±0.95 | 4.81±0.98 | 4.42±1.22 | 3.93±1.12 | 0.000 |
| Total cholesterol (mg/dL) | 4.20±1.23 | 4.08±1.01 | 4.17±1.21 | 4.16±1.23 | 0.926 |
| HDL | 1.05±0.32 | 1.00±0.24 | 1.02±0.34 | 1.03±0.34 | 0.881 |
| LDL | 2.52±1.05 | 2.49±0.88 | 2.50±0.95 | 2.54±1.04 | 0.952 |
| Triglycerides (mg/dL) | 1.95±1.20 | 1.80±0.94 | 1.91±1.10 | 1.97±1.30 | 0.668 |
| C-reactive protein (mg/L) | 81.23±15.66 | 78.41±16.32 | 77.02±14.62 | 75.48±15.84 | 0.082 |
| Fasting glucose (mg/dL) | 6.05±2.07 | 5.73±1.42 | 5.87±1.78 | 5.83±1.71 | 0.778 |
| Cardiovascular medication | |||||
| Aspirin | 42 (95.45%) | 89 (97.80%) | 224 (96.55%) | 280 (97.56%) | 0.482 |
| Beta-blockers | 40 (90.91%) | 82 (90.11%) | 202 (87.07%) | 237 (82.58%) | 0.203 |
| ACE-Is or ARBs | 21 (47.73%) | 26 (28.57%) | 82 (35.34%) | 103 (35.89%) | 0.185 |
| Calcium channel blockers | 15 (34.09%) | 35 (38.46%) | 76 (32.76%) | 103 (35.89%) | 0.797 |
| Nitrates | 41 (93.18%) | 86 (94.51%) | 209 (90.09%) | 264 (91.99%) | 0.765 |
| Statin | 31 (70.45%) | 54 (59.34%) | 129 (55.60%) | 157 (54.70%) | 0.238 |
Data are reported as means±SD or the number (%) of patients. BMI: body mass index; MI: myocardial infarction; PCI: percutaneous coronary intervention; LP(a): lipoprotein(a); Lg: logarithm; HDL: high-density lipoprotein; LDL: low-density-lipoprotein; ACE-Is: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers. Statistical analysis was done with ANOVA or the chi-square test.
Coronary angiographic findings of the patients.
| Variables | Rentrop classification | P | |||
|---|---|---|---|---|---|
| 0 (n=44) | 1 (n=91) | 2 (n=232) | 3 (n=287) | ||
| LAD | 19 (43.18%) | 43 (47.25%) | 88 (37.93%) | 93 (32.40%) | 0.058 |
| LCX | 17 (38.64%) | 42 (46.15%) | 88 (100%) | 90 (96.05%) | 0.065 |
| RCA | 11 (25%) | 34 (37.36%) | 118 (50.86%) | 195 (67.94%) | <0.001 |
| One-vessel disease | 41 | 68 | 179 | 210 | |
| Two-vessel disease | 3 | 20 | 45 | 69 | |
| Three-vessel disease | 0 | 3 | 8 | 8 | 0.149 |
Data are reported as number (%). LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery. Statistical analysis was done with the chi-square test.
Multivariate logistic regression for the presence of coronary collaterals according to lipoprotein(a) levels.
| n | Rentrop | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | Odds ratio (95%CI) | P | Odds ratio (95%CI) | P | ||
| Lp(a) - Model 1 | |||||||||
| <7.17 | 218 | 13 (5.96) | 20 (9.17) | 70 (32.11) | 115 (52.75) | 1 | 1 | ||
| 7.17-13.50 | 218 | 6 (2.75) | 19 (8.72) | 72 (33.03) | 121 (55.50) | 0.85 (0.59-1.22) | 0.377 | 0.84 (0.58-1.21) | 0.349 |
| >13.50 | 218 | 25 (11.47) | 52 (23.85) | 90 (41.28) | 51 (23.39) | 3.38 (2.36-4.85) | <0.001 | 3.34 (2.32-4.83) | <0.001 |
| Lp(a) - Model 2 | |||||||||
| ≤30.00 | 571 | 30 (5.25) | 63 (11.03) | 191 (33.45) | 287 (50.26) | 1 | 1 | ||
| >30.00 | 83 | 14 (16.87) | 28 (33.73) | 41 (49.40) | 0 (0.00) | 6.87 (4.41-10.7) | <0.001 | 6.77 (4.44-10.4) | <0.001 |
Data are reported numbers (%). The final models were adjusted for age, gender, body mass index, current smoking, diabetes mellitus, and number of diseased vessels. Lp(a): lipoprotein(a); CI: confidence interval.